Abstract

Hyperdiploidy, i.e. gain of whole chromosomes, is one of the most common genetic features of childhood acute lymphoblastic leukemia (ALL), but its pathogenetic impact is poorly understood. Here, we report a proteogenomic analysis on matched datasets from genomic profiling, RNA-sequencing, and mass spectrometry-based analysis of >8,000 genes and proteins as well as Hi-C of primary patient samples from hyperdiploid and ETV6/RUNX1-positive pediatric ALL. We show that CTCF and cohesin, which are master regulators of chromatin architecture, display low expression in hyperdiploid ALL. In line with this, a general genome-wide dysregulation of gene expression in relation to topologically associating domain (TAD) borders were seen in the hyperdiploid group. Furthermore, Hi-C of a limited number of hyperdiploid childhood ALL cases revealed that 2/4 cases displayed a clear loss of TAD boundary strength and 3/4 showed reduced insulation at TAD borders, with putative leukemogenic effects.

High hyperploidy is a common feature in childhood B-cell precursor acute lymphoblastic leukemia. Here, the authors perform proteogenomic and Hi-C analyses of this leukemia and the ETV6/RUNX1 subtype and show that CTCF and cohesin expression are low in hyperdiploid cases and transcriptional dysregulation in relation to topologically associating domain borders in some of these cases.

Details

Title
Proteogenomics and Hi-C reveal transcriptional dysregulation in high hyperdiploid childhood acute lymphoblastic leukemia
Author
Yang, Minjun 1   VIAFID ORCID Logo  ; Vesterlund Mattias 2   VIAFID ORCID Logo  ; Siavelis Ioannis 2 ; Moura-Castro, Larissa H 1 ; Castor, Anders 3 ; Fioretos Thoas 1 ; Jafari Rozbeh 2   VIAFID ORCID Logo  ; Lilljebjörn Henrik 1   VIAFID ORCID Logo  ; Odom, Duncan T 4   VIAFID ORCID Logo  ; Olsson, Linda 5 ; Ravi Naveen 1 ; Woodward, Eleanor L 1 ; Harewood, Louise 6 ; Lehtiö Janne 2   VIAFID ORCID Logo  ; Paulsson Kajsa 1   VIAFID ORCID Logo 

 Lund University, Division of Clinical Genetics, Department of Laboratory Medicine, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361) 
 Science for Life Laboratory and Karolinska Institute, Clinical Proteomics Mass Spectrometry, Department of Oncology-Pathology, Stockholm, Sweden (GRID:grid.452834.c) 
 Skåne University Hospital, Lund University, Department of Pediatrics, Lund, Sweden (GRID:grid.4514.4) 
 University of Cambridge, Li Ka Shing Centre, Cancer Research UK Cambridge Institute (CRUK-CI), Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); Division of Signaling and Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584) 
 Lund University, Division of Clinical Genetics, Department of Laboratory Medicine, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361); Office for Medical Services, Division of Laboratory Medicine, Department of Clinical Genetics and Pathology, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361) 
 University of Cambridge, Li Ka Shing Centre, Cancer Research UK Cambridge Institute (CRUK-CI), Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); Queen’s University Belfast, Precision Medicine Centre of Excellence, Belfast, UK (GRID:grid.4777.3) (ISNI:0000 0004 0374 7521) 
Publication year
2019
Publication date
Dec 2019
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2202771381
Copyright
© The Author(s) 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.